AZD-8055

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameAZD-8055
Drug Alias NameAZD-8055
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionmTOR Complex 2 inhibitorsMammalian target of Rapamycin (mTORC1) inhibitors
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2
Therapy Area/IndicationsSolid tumoursCarcinoma, HepatocellularOligodendroglioma +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomFrance +[6] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Pharmaceutical Co LtdAstrazeneca PlcNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, HepatocellularOligodendroglioma +[8] 

Other Information

ATC CodeN/A
Related LinksN/A